"Impact of a rash management guide in patients receiving apalutamide fo" by Neal Shore, Jason Hafron et al.
 

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.

Document Type

Article

Publication Date

7-5-2024

Publication Title

Prostate cancer and prostatic diseases

Abstract

BACKGROUND/OBJECTIVES: Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.

SUBJECTS/METHODS: A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.

RESULTS: Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.

CONCLUSIONS: Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.

Volume

Online ahead of print

DOI

10.1038/s41391-024-00858-4

ISSN

1476-5608

PubMed ID

38969791

Link to Full Text

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 3
  • Usage
    • Abstract Views: 6
  • Captures
    • Readers: 5
  • Mentions
    • News Mentions: 1
see details

Share

COinS